Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream

Journal of the American Academy of Dermatology

Volumn 46, Issue 4, 2002, Pages 545-548

  Schroeder, Theresa L ^a   Sengelmann, Roberta D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; ARTICLE; BLISTER; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CASE REPORT; CLINICAL FEATURE; DEFORMITY; DISEASE COURSE; DOSE RESPONSE; ERYTHEMA; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MORBIDITY; PAIN; PENIS CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SCAR; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036553654     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120444     Document Type: Article

References (31)

1. Graham JH, Helwig EB. Erythroplasia of Queyrat: a clinicopathologic and histochemical study. Cancer 1973;32:1396-414.
2. Moritz DL, Lynch WS. Extensive Bowen's disease of the penile shaft treated with fresh tissue Mohs micrographic surgery in two separate operations. J Dermatol Surg Oncol 1991;17:374-8.
3. Mohs FE, Snow SN, Messing EM, Kuglitsch ME. Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 1985;133:961-6.
4. Brown MD, Zachary CB, Grekin RC, Swanson NA. Penile tumors: their management by Mohs micrographic surgery. J Dermatol Surg Oncol 1987;13:1163-7.
5. Kaye V, Zhang G, Dehner LP, Fraley EE. Carcinoma in situ of penis: is distinction between erythroplasia of Queyrat and Bowen's disease relevant? Urology 1990;36:479-82.
6. Goette DK, Carson TE. Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. Cancer 1976;38:1498-502.
7. Tolia BM, Castro VL, Mouded IM, Newman HR. Bowen's disease of shaft of penis: successful treatment with 5-fluorouracil. Urology 1976;7:617-9.
8. Blank AA, Schnyder UW. Soft-x-ray therapy in Bowen's disease and erythroplasia of Queyrat. Dermatologica 1985;171:89-94.
9. Rosemberg SK, Fuller TA. Carbon dioxide rapid superpulsed laser treatment of erythroplasia of Queyrat. Urology 1980;16:181-2.
10. Sonnex TS, Ralfs IG, Plaza De Lanza M, Dawber RPR. Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery. Br J Dermatol 1982;106:581-4.
11. Harth YH, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol Surg 1998;24:723-6.
12. Stables GI, Stringer MR, Robinson DJ, Ash DV. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999;140:514-7.
13. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
14. Cook JR, Hill DA, Humphrey PA, Pfeifer JD, El-Mofty SK. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol 2000;13:914-8.
15. Persky L. Epidemiology of cancer of the penis. Recent Results Cancer Res 1977;60:97-109.
16. Schellhammer PF, Grabstalk H. Tumors of the penis. In: Campbell MF, editor. Philadelphia: Saunders; 1986. p. 1588-603.
17. Ross BS, Levine VJ, Dixon C, Ashinoff R. Squamous cell carcinoma of the penis in circumcised man: a case for dermatology and urology, and review of the literature. Cutis 1998;61:41-3.
18. Ikenberg H, Gissman L, Gross G, Grussendorf-Cohen El, Hausen H. Human papilloma type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer 1983;32:563-5.
19. Nordquist RE, Olson RL, Everett MA, Condit PT. Virus-like particles in Bowen's disease. Cancer Res 1970;30:288-93.
20. Wiener JS, Effert PJ, Humphrey PA, Yu L, Liu ET, Walther PJ. Prevalence of human papillomavirus types 16 and 18 in squamous-cell carcinoma of the penis: a retrospective analysis of primary and metastatic lesions by differential polymerase chain reaction. Int J Cancer 1992;50:694-701.
21. Tyring SK, Arany I, Stanley MA,Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condyloma acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
22. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58:365-72.
23. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs 1998;7:437-49.
24. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9.
25. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-41.
26. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, et al. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.
27. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
28. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-9.
29. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox RL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
30. Beutner KR, Spruance SL, Houghham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
31. Coskey RJ, Mehregan AJ, Bryan HG. Bowen's disease: unsuccessful response to topical 5-fluorouracil therapy. Cutis 1969;5:1109-12.